Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871783 | PMC |
| http://dx.doi.org/10.1186/s12967-025-06272-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Revisiting ABCB1 polymorphism: a missing piece in Alzheimer's risk and treatment?
J Transl Med
February 2025
Geriatrics Department, Fernand Widal Lariboisière University Hospital, GHU APHP.Nord, Paris, France.
Revisiting ABC Transporters and Their Clinical Significance in Glioblastoma.
Pharmaceuticals (Basel)
January 2025
Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia.
: The multiple drug-resistant phenomenon has long since plagued the effectiveness of various chemotherapies used in the treatment of patients with glioblastoma (GBM), which is still incurable to this day. ATP-binding cassette (ABC) transporters function as drug transporters and have been touted to be the main culprits in developing resistance to xenobiotic drugs in GBM. : This review systematically analyzed the efficacy of ABC transporters against various anticancer drugs from 16 studies identified from five databases (PubMed, Medline, Embase, Scopus, and ScienceDirect).
View Article and Find Full Text PDFRevisiting the role of ABC transporters in multidrug-resistant cancer.
Nat Rev Cancer
July 2018
Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Most patients who die of cancer have disseminated disease that has become resistant to multiple therapeutic modalities. Ample evidence suggests that the expression of ATP-binding cassette (ABC) transporters, especially the multidrug resistance protein 1 (MDR1, also known as P-glycoprotein or P-gp), which is encoded by ABC subfamily B member 1 (ABCB1), can confer resistance to cytotoxic and targeted chemotherapy. However, the development of MDR1 as a therapeutic target has been unsuccessful.
View Article and Find Full Text PDFImaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
Eur J Pharm Sci
August 2016
Imagerie Moléculaire In Vivo, IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, CEA-SHFJ, Orsay, France. Electronic address:
Cyclosporin A (CsA) and dipyridamole (DPy) are potent inhibitors of the P-glycoprotein (P-gp; ABCB1) in vitro. Their efficacy at inhibiting P-gp at the blood-brain barrier (BBB) is difficult to predict. Efficient and readily available (i.
View Article and Find Full Text PDFThe Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene.
J Natl Cancer Inst
September 2015
Laboratory of Cell Biology (MMG) and Laboratory of Molecular Biology (IHP), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.